# Alivus Life Sciences Ltd (ALIVUS)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1039
Day Change: -1.66%
52W High: ₹1155.2
52W Low: ₹819
Market Cap: ₹12,953 Cr

## Valuation
P/E: 23.01
P/B: 3.89
EPS: ₹45.86
Book Value: ₹271.02
Dividend Yield: 0%

## Returns
1Y Return: 14.34%

## Profitability
ROE: 18.36%
ROCE: 34.9%
Debt/Equity: 0.02
Revenue Growth: 9.6%
Profit Growth: 14.5%
EBITDA Margin: 32.83%
Operating Margin: 30.5%

## About
Alivus Life Sciences Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Alivus Life Sciences Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Investor Presentation: Announcement under Regulation 30 (LODR)-Investor Presentation
- GuruFocus.com: Alivus Life Sciences Ltd (BOM:543322) Q4 2026 Earnings Call Highlights: Record EBITDA Margins ...

## Data Freshness
Quote Updated: 2026-05-24T20:00:00.754Z
Price History Updated: 2026-05-17T21:24:01.348Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:24:01.348Z
Quant Updated: 2026-05-17T21:24:01.348Z
Sentiment Updated: 2026-05-17T21:24:01.348Z
Financials Status: current
Financials Updated: 2026-05-18T10:30:59.054Z
Financials Last Attempt: 2026-05-18T10:30:59.054Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2020)
Revenue: ₹886 Cr
Operating Profit: ₹248 Cr (OPM 28%)
Net Profit: ₹196 Cr
Tax: ₹228 Cr

## Annual P&L History
Mar 2020: Rev ₹886Cr | PAT ₹196Cr | OPM 28%
Mar 2021: Rev ₹1537Cr | PAT ₹313Cr | OPM 31%

## Balance Sheet (FY25)
Total Assets: ₹3411.45 Cr
Total Liabilities: ₹594.08 Cr
Borrowings: ₹56.61 Cr
Cash: ₹71.06 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Yasir Yusufali Rawjee Ph.D., CEO, MD & Director
- Tushar P. Mistry, Senior VP & CFO
- Rudalf Joseph Corriea, Company Secretary & Compliance Officer
- Vinod  Naik, Group VP, Head of Technical Operations & Whole Time Director
- Soumi  Rao, General Manager of Corporate Communications

---
Source: rupiya.io/stocks/alivus
Disclaimer: For research and education only. Not investment advice.